Clinical Research Directory

Inclusion Criteria: 1. Age: Male patients aged 18 years and older. 2. Diagnosis: Patients who are suspected of having prostate cancer based on clinical data and standard diagnostic protocols. 3. Disease Stage: Patients at any stage of suspected prostate cancer (localized, locally advanced, or metastatic). 4. Consent: Ability and willingness to provide written informed consent. 5. Clinical Data Availability: Availability of comprehensive clinical data. 6. Sample Provision: Willingness to provide blood and/or tissue samples for genetic and inflammatory marker analysis. Exclusion Criteria: 1. Prior Treatment: Patients who have undergone any prior prostate cancer treatments such as surgery, radiation therapy, or systemic therapies (e.g., hormone therapy, chemotherapy). 2. Other Malignancies: Presence of other concurrent malignancies, except for adequately treated basal cell or squamous cell skin cancer. 3. Severe Comorbidities: Patients with severe or uncontrolled comorbid conditions that could interfere with study participation or data interpretation (e.g., severe cardiovascular, pulmonary, hepatic, or renal diseases). 4. Infection: Active infections or other severe medical conditions that could compromise patient safety or study integrity. 5. Non-compliance: Inability to comply with study procedures, follow-up requirements, or any condition that, in the investigator's opinion, could interfere with study participation. 6. Medication Use: Use of medications that could interfere with the study results, such as immunosuppressive drugs. Additional Considerations: * Screening: All potential participants will undergo a screening process to verify eligibility criteria. * Confidentiality: Ensure all patient data is handled in accordance with privacy regulations and ethical guidelines. * Follow-Up: Participants should be willing to attend regular follow-up visits for ongoing data collection and monitoring of disease progression and treatment response. By setting these criteria, the study aims to create a well-defined patient cohort for evaluating the relationship between genetic and inflammatory markers and prostate cancer aggressiveness.